Scientists identify key molecular regulator of cardiac hypertrophy

Jul 18, 2010

Scientists have identified a key molecular regulator of cardiac hypertrophy (enlargement of the heart) that may provide a therapeutic target for a major risk factor of heart failure and early death.

The researchers report in an upcoming edition of Nature Medicine that over-expression of the protein CIB1 (also called calmyrin) triggers biochemical processes that lead to . This includes activating the enzyme calcineurin, a key biochemical component in the normal development and function of .

The study was posted online July 18 in advance of publication.

"Hypertrophic heart disease is a leading health problem in Western Countries. Our data clearly show that CIB1 is required for permitting activation of calcineurin during maladaptive cardiac hypertrophy," said Jeffery Molkentin, Ph.D., lead investigator and a researcher in the division of Molecular Cardiovascular Biology at Cincinnati Children's Hospital Medical Center and a Howard Hughes Medical Institute investigator. "This suggests a new strategy for treating hypertrophic heart disease through inhibition of CIB1 or its interaction with calcineurin."

Pre-existing cardiac hypertrophy from chronic health conditions like hypertension (high blood pressure) or a history of heart attacks is a major risk factor for . After these conditions damage the heart, called cardiomyocytes enlarge as the body tries to respond and compensate, increasing the organ's size.

The researchers first set out to identify previously unknown regulators of cardiomyocyte growth during hypertrophy. This was done through genetic analysis of neonatal rat heart cells cultured in the laboratory and programmed to become hypertrophic. Genetic screens detected elevated levels of CIB1 - which helps mediate biochemical processes in the plasma membranes of various mouse and human tissues, especially the heart - and identified the protein as a prime candidate.

Additional analysis of hypertrophied mouse and human heart tissue also detected elevated levels of CIB1 in the sarcolemma, the thin plasma membrane surrounding heart muscle fiber that is important to receiving and serving as a conductor of stimuli.

In experiments designed to monitor the levels, function and molecular interactions of CIB1 during heart injury in living organisms, the scientists conducted hypertension simulation tests on mice. Mice were generated that either lack the CIB1 gene or that over express CIB1 in the heart. Mice with over-expressed cardiac-specific CIB1 exhibited pronounced and dysfunction with hypertension stimulation, but mice lacking the CIB1 gene showed protection from hypertrophy and dysfunction.

Although the study points to CIB1 and its interaction with calcineurin as possible therapeutic targets, Dr. Molkentin cautioned that extensive additional research is needed before the data becomes clinically applicable to patients.

Explore further: Study finds enzyme inhibitors suppress herpes simplex virus replication

Related Stories

Research uncovers new steps on pathway to enlarged heart

Oct 23, 2008

Researchers have new insight into the mechanisms that underlie a pathological increase in the size of the heart. The research, published by Cell Press in the October 24th issue of the journal Molecular Cell, may lead to the ...

Recommended for you

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.